TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Feb 14, 2023 11:57 JST
Source:
Ocumension Therapeutics
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results
Total Revenue And Gross Profit Expected To Surge Of Between 176% And 183% And 171% to 179% Respectively
HONG KONG, Feb 14, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, is pleased to announce that it is anticipated that the Company will record a significant increase in its revenue and gross profit for the year ended 31 December 2022 (the "Year 2022").
The Company expects to record a total revenue of approximately RMB 155 million to 159 million for the Year 2022, representing a year-on-year increase of approximately 176% to 183% compared with the total revenue of approximately RMB 56.1 million for the Year 2021. In addition, the total gross profit is approximately RMB 100 million to 103 million, representing a year-on-year increase of approximately 171% to 179% compared with the total gross profit of approximately RMB 36.9 million for the Year 2021.
The increase in the total revenue and the gross profit in 2022 is mainly attributable to the commercialization of the Company's Core Product, OT-401 (fluocinolone intravitreal implant, trade name: Youshiying, as well as the increase in the revenue generated from sales of ophthalmic products, including Ou Qin, brimonidine tartrate eye, among others; and the increase in the revenue generated from the pharmaceutical products promotion services.
Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "With effective quarantine measures taken by the Chinese government to reduce confirmed COVID-19 cases in China, as well as the various precautionary measures implemented by us to adjust our employees' work arrangements in accordance with the relevant regulations and policies, we were able to maintain a sufficient number of personnel to continue working on-site or off-site to ensure minimum disruption to our business operation and R&D activities. Meanwhile, our sales of ophthalmic products were affected by the lockdown of certain areas in China due to the COVID-19 pandemic. However, with the acceleration of expansion to hospitals in regions not subject to the lockdown during the Reporting Period and the continuous increase in sales volume. Ocumension has proven that it was the leader in the R&D of ophthalmic drugs in China, with the commercialization of the Core Product, we will continue moving forward on the path to become a fully integrated leader in the ophthalmic drug industry in China."
About Ocumension Therapeutics
Ocumension Therapeutics is a Chinese ophthalmology platform company dedicated to identifying, developing and commercializing pioneering or best-in-class ophthalmic therapies. The company's vision is to provide world-class drug solutions to meet the huge demand for ophthalmology treatments in China. We believe that our ophthalmology platform with its obvious first-mover advantage will give us a leading position in the ophthalmology industry in China. Up to now, the company has 24 kinds of drug assets in front of the eye and back of the eye, and has established a complete ophthalmic drug product line, six of which have entered phase III clinical trials in China. On July 10, 2020, Ocumension was listed on the main board of the Stock Exchange of Hong Kong Limited (stock code: 01477).
More information about Ocumension Therapeutics:
https://www.ocumension.com/
Source: Ocumension Therapeutics
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema
December 20 2023 20:51 JST
Ocumension Therapeutics Announces 2023 Interim Results
August 24 2023 23:35 JST
Ocumension Therapeutics Announces 2022 Annual Results
March 30 2023 22:29 JST
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
March 13 2023 18:30 JST
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202
February 03 2023 10:01 JST
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China
February 01 2023 10:00 JST
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively
January 30 2023 11:38 JST
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
March 20 2021 10:10 JST
More Press release >>
Latest Press Release
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
May 02, 2024 22:13 JST
Four-strong TOYOTA GAZOO Racing squad to push for more Portugal success
May 02, 2024 18:05 JST
Spectacular Spa awaits TOYOTA GAZOO Racing
May 02, 2024 17:46 JST
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
May 02, 2024 11:00 JST
Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub
Apr 30, 2024 19:08 JST
SPARX Group Establishes Space Frontiers Second Fund
Apr 29, 2024 18:49 JST
MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam"
Apr 29, 2024 18:00 JST
POSCO Future M and Honda Reach Basic Agreement on Collaboration for Production of Cathode Materials for Automotive Batteries in Canada
Apr 29, 2024 14:25 JST
Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada
Apr 29, 2024 14:16 JST
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
More Latest Release >>